Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease

RN Hardwick, CD Fisher, MJ Canet, AD Lake… - Drug metabolism and …, 2010 - ASPET
Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of
Americans, encompasses progressive stages of liver damage ranging from steatosis to …

Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease

…, P Novak, CD Fisher, JP Jackson, RN Hardwick… - Drug metabolism and …, 2011 - ASPET
Nonalcoholic fatty liver disease (NAFLD) is characterized by a series of pathological changes
that range from simple fatty liver to nonalcoholic steatohepatitis (NASH). The objective of …

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease

AD Lake, P Novak, RN Hardwick… - Toxicological …, 2014 - academic.oup.com
Nonalcoholic fatty liver disease (NAFLD) may progress from simple steatosis to severe,
nonalcoholic steatohepatitis (NASH) in 7%–14% of the US population through a second “hit” in …

Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease

RN Hardwick, CD Fisher, MJ Canet, GL Scheffer… - Drug metabolism and …, 2011 - ASPET
Transporters located on the sinusoidal and canalicular membranes of hepatocytes regulate
the efflux of drugs and metabolites into blood and bile, respectively. Changes in the …

Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease

RN Hardwick, DW Ferreira, VR More, AD Lake… - Drug metabolism and …, 2013 - ASPET
The UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) represent major
phase II drug-metabolizing enzymes that are also responsible for maintaining cellular …

Microphysiological systems evaluation: experience of TEX-VAL tissue chip testing consortium

…, V Bhaskaran, M Davis, RN Hardwick… - Toxicological …, 2022 - academic.oup.com
Much has been written and said about the promise and excitement of microphysiological
systems, miniature devices that aim to recreate aspects of human physiology on a chip. The …

Impaired N‐linked glycosylation of uptake and efflux transporters in human non‐alcoholic fatty liver disease

JD Clarke, P Novak, AD Lake, RN Hardwick… - Liver …, 2017 - Wiley Online Library
Background & Aims N‐linked glycosylation of proteins is critical for proper protein folding and
trafficking to the plasma membrane. Drug transporters are one class of proteins that have …

Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS …

…, C Frantz, A Fullerton, J Gan, RN Hardwick… - ALTEX-Alternatives to …, 2022 - altex.org
Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug
attrition due to safety and/or efficacy concerns. For this technology to have an impact, the …

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models

MJ Canet, RN Hardwick, AD Lake, AL Dzierlenga… - Drug Metabolism and …, 2014 - ASPET
Nonalcoholic fatty liver disease is a prevalent form of chronic liver disease that can progress
to the more advanced stage of nonalcoholic steatohepatitis (NASH). NASH has been shown …

A two-way interaction between methotrexate and the gut microbiota of male sprague–dawley rats

…, JAK McDonald, RN Hardwick… - Journal of proteome …, 2020 - ACS Publications
Methotrexate (MTX) is a chemotherapeutic agent that can cause a range of toxic side effects
including gastrointestinal damage, hepatotoxicity, myelosuppression, and nephrotoxicity …